Articles related to Clinical Pharmacology

In 2023, patents for the two blockbusters Humira and Stelara will expire. The patents for Aranesp, Rituxan, Simponi, and others will expire in 2024, and in 2025, six more blockbuster drugs will experience patent expiration, opening the field to a rush of biosimilars. That could create an environment of significantly reduced drug prices.

The evidence for NAD supplement effectiveness at present comes only from animal models and very small-scale human studies. And some studies link excessive consumption of NADH to anxiety and insomnia, and NAD precursors to Parkinson’s disease and diabetes.

The recent United States Supreme Court ruling raises the bar for evidence that must be shown by the government in order to successfully prosecute doctors who prescribe excessive dosages of painkillers — a huge win for prescribers.

After completing this activity, participants will be better equipped to discuss the major difficulties in managing MDR HIV and to illustrate the promise of both existing and forthcoming MDR HIV medicines.

The survey examined the methods used by payors to collect and monitor social determinants of health (SDOH), their high-priority disease states, the measures they feel are necessary to address disparities, how they believe those measures will affect how people access and use medications, and their ongoing and future efforts in this area.

Sufentanil sublingual tablet 30 mcg (Dsuvia, AcelRx), an effective novel tablet formulation of the synthetic opioid sufentanil, has been given FDA approval for the management of severe acute pain in adult patients in licensed medically supervised healthcare settings. The medication is administered sublingually in a single-dose, prefilled applicator.